{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=36",
    "query": {
      "condition": "Phase 1",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 18611,
    "total_pages": 1862,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=37&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=35&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T10:10:24.224Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00439803",
      "title": "A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Infections"
      ],
      "interventions": [
        {
          "name": "AVX601",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AlphaVax, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 40,
      "start_date": "2007-04",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2008-11-10",
      "last_synced_at": "2026-10-29T10:10:24.224Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00439803"
    },
    {
      "nct_id": "NCT00565227",
      "title": "Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small-Cell Lung Carcinoma",
        "Prostate Cancer",
        "Bladder Cancer",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "vorinostat (suberoylanilide hydroxamic acid)",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2007-04",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2016-12-02",
      "last_synced_at": "2026-10-29T10:10:24.224Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00565227"
    },
    {
      "nct_id": "NCT01068327",
      "title": "Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenocarcinoma of the Pancreas",
        "Stage III Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "nelfinavir mesylate",
          "type": "DRUG"
        },
        {
          "name": "stereotactic body radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "hypofractionated radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2007-11-05",
      "completion_date": "2015-02-01",
      "has_results": false,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-10-29T10:10:24.224Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01068327"
    },
    {
      "nct_id": "NCT00664586",
      "title": "A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Solid Tumors",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Terameprocol (EM-1421)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Erimos Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2007-05",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2016-02-23",
      "last_synced_at": "2026-10-29T10:10:24.224Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00664586"
    },
    {
      "nct_id": "NCT00000773",
      "title": "Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pneumonia, Pneumocystis Carinii",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Atovaquone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "1 Month to 12 Years"
      },
      "enrollment_count": 24,
      "start_date": null,
      "completion_date": "1996-09",
      "has_results": false,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-10-29T10:10:24.224Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000773"
    },
    {
      "nct_id": "NCT03690154",
      "title": "A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Solid Tumors",
        "Acute Myeloid Leukemia Refractory",
        "Acute Myeloid Leukemia, in Relapse"
      ],
      "interventions": [
        {
          "name": "FN-1501",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2018-07-23",
      "completion_date": "2022-02-11",
      "has_results": false,
      "last_update_posted_date": "2023-10-13",
      "last_synced_at": "2026-10-29T10:10:24.224Z",
      "location_count": 2,
      "location_summary": "Fairway, Kansas • Detroit, Michigan",
      "locations": [
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03690154"
    },
    {
      "nct_id": "NCT06004245",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "VVD-133214",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vividion Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2024-01-25",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-10-29T10:10:24.224Z",
      "location_count": 18,
      "location_summary": "Tucson, Arizona • Duarte, California • Irvine, California + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06004245"
    },
    {
      "nct_id": "NCT05412472",
      "title": "Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "GC4419",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 26,
      "start_date": "2019-04-04",
      "completion_date": "2021-04-06",
      "has_results": false,
      "last_update_posted_date": "2022-06-09",
      "last_synced_at": "2026-10-29T10:10:24.224Z",
      "location_count": 2,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05412472"
    },
    {
      "nct_id": "NCT02725372",
      "title": "Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Inhaled Nitric Oxide 75 mcg/kg IBW/hr",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bellerophon Pulse Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 207,
      "start_date": "2016-04",
      "completion_date": "2018-08",
      "has_results": true,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-10-29T10:10:24.224Z",
      "location_count": 37,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02725372"
    },
    {
      "nct_id": "NCT02507583",
      "title": "Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "david andrews",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2015-09-01",
      "completion_date": "2020-08-17",
      "has_results": false,
      "last_update_posted_date": "2025-05-07",
      "last_synced_at": "2026-10-29T10:10:24.224Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02507583"
    }
  ]
}